Saris, C.J.
The defendants, Everlight and Epistar, have asserted the affirmative defense of laches, alleging that they should not be liable for any pre-suit damages because the plaintiff, Trustees of Boston University (BU), unreasonably delayed in filing suit against them, and this delay caused the defendants material economic prejudice. BU responds that any delay was excusable due to its other active patent cases and because the defendants have not proven that they would have changed their infringing behavior had BU sued earlier. BU has moved for prejudgment and postjudgment interest and an entry of judgment. After a jury trial and two-day laches bench trial, the Court finds for the plaintiff on the issue of laches and
On November 11, 1997, the U.S. Patent and Trademark Office (PTO) issued patent number 5,686,738 ('738 patent), entitled "Highly Insulating Monocrystalline Gallium Nitride Thin Films," naming Theodore Moustakas as the inventor and BU as the assignee. Gallium Nitride (GaN) thin films are common components of blue light-emitting diodes (LEDs). LEDs are semiconductor devices that emit light when charged with an electric current. LEDs containing GaN thin films can be found in light bulbs, laser printers, optical-fiber communication networks, and flat-panel displays of handheld devices and televisions.
On March 26, 2001, BU and Cree, an LED manufacturing company, entered into an exclusive license agreement, which required Cree to implement a program to enforce the '738 patent against infringers, but did not require Cree to bring more than one infringement lawsuit at a time. From May 3, 2001 until the current case was filed, Cree and BU were engaged in six lawsuits to enforce the '738 patent:
Case Name Date Filed Date Terminated BU v. Nichia Corp. 5/3/2001 11/26/2002 BU v. Nichia Corp. 5/3/2001 10/30/2001 BU v. AXT Inc. 6/10/2003 4/19/2004 Cree, Inc., v. Bridgelux, Inc. 9/11/2006 8/21/2007 Bridgelux, Inc. v. Cree, Inc. 10/17/2006 1/7/2009 Honeywell Int'l Inc. v. Philips 4/30/2008 3/6/2009
Docket No. 1669 at 3. Starting in March 2011, BU and Cree began discussions to amend their license agreement so that BU could prosecute infringement actions on its own behalf. On January 30, 2012, BU and Cree ended their exclusive license arrangement and BU took back control of the '738 patent.
Epistar and Everlight are different corporations with close ties. In 2006, Everlight's chairman of the board, Robert Yeh, was also the vice chairman of the board of Epistar. From 2006 to 2012, Everlight was one of Epistar's largest single shareholders and controlled over $100 million in Epistar stock. Everlight held itself out to customers as being vertically integrated with Epistar and used this relationship for marketing purposes. Epistar is indemnifying Everlight for all legal expenses in defending this suit because Epistar's chips are inside of the accused Everlight LED packages.
On October 17, 2012, BU filed the present action against Everlight and, on December 14, 2012, filed suit against Epistar. Epistar and Everlight continued selling the accused infringing products after BU filed suit.
One key issue in the laches inquiry is when the plaintiff knew about the defendants' infringement. In some circumstances, the plaintiff's knowledge of infringement by a defendant's predecessor company can start the period of delay with respect to laches. In April 2002, in a draft internal presentation, BU's current head of licensing, Michael Pratt, wrote that United Epitaxy was part of a large group of companies in the LED market whose products infringed on the '738 patent. In August 2005, United Epitaxy merged with Epistar, a merger covered widely in industry journals. There is no evidence that Epistar continued to manufacture any of United Epitaxy's products post-merger.
On February 7, 2005, Cree sent a letter accusing another company, Epitech, of infringing the '738 patent. In the following months, the parties engaged in additional written correspondence regarding Cree's allegations. On October 25, 2005, Cree terminated the exchange in a letter advising Epitech that it "will vigorously enforce its patent rights against Epitech if Epitech manufactures, uses, offers to sell or sells its infringing LEDs in the United States." PTX 1520.
In October 2010, representatives of Cree and Epistar met for the first time to discuss licensing Cree's LED patent portfolio, which included the '738 patent. In these discussions, Cree never accused Epistar of infringing the '738 patent.
The second key issue in a laches inquiry is whether the defendant suffered any harm caused by the plaintiff's delay in filing suit. On September 28, 2006, Epistar spent $322 million to merge with Epitech. Meng Kuo, the director of Epistar's intellectual property division, never discovered Cree's letter accusing Epitech of infringement, despite her direct involvement in the due diligence for the merger. She credibly claimed that if Epistar had known about a possible infringement claim, it would have negotiated a lower price or contractual provisions protecting it from liability. Significantly, one month after Epistar acquired Epitech, it discontinued all of Epitech's products.
In April 2007, Cree accused Epistar's customer, Everlight, of infringing on the '738 patent. Because the accused products contained Epistar chips, Everlight immediately turned to Epistar for help defending against Cree's accusation. At this point, no court had construed the claim term "grown on" in the '738 patent. Epistar interpreted the term to mean that the buffer layer was the first layer immediately above the sapphire substrate. According to Epistar, the first layer in its chip was single crystalline aluminum nitride. The '738 patent claims a non-single crystalline gallium nitride buffer layer, so Epistar took the position that its chips did not infringe the patent and provided a report to that effect to Everlight in January 2008. Around this time in early 2008, Epistar became aware of Cree's ongoing litigation with Bridgelux, one of Epistar's customers, over the '738 patent. In August 2008, the court in the Bridgelux litigation construed the term "on" to mean "positioned indirectly or directly above."
In 2007, Epistar had only $48,913 in accused sales which increased to $47.4 million in 2011. From 2011 to 2013, Epistar's sales and shipments of GaN LED chips to the United States accounted for less than 0.2% of its worldwide sales. When BU sued Epistar in 2012, it did not alter its production or sales methods to avoid infringement. Kuo testified that because the patent was set to expire in 2014, there was little financial incentive for Epistar to adjust its supply relationships, design around the '738 patent, or seek a licensing agreement after BU sued. However, Epistar, through its business relationship with Everlight, knew in 2007 that Cree had accused its chips of infringing on the '738 patent. Epistar did nothing to change its behavior, even though seven years were left on the life of the patent. This Court finds that the primary reason that Epistar did not change its behavior was its persistent belief it did not infringe.
In May 2004, Cree accused Fairchild Semiconductor of infringing the '738 patent, but never followed up on its accusation. At the time of Cree's accusation, Everlight manufactured LED products for Fairchild based on Fairchild's specifications and Fairchild sold these products all over the world. In order to cut out the middleman, Everlight acquired Fairchild's LED business assets in early 2006. Cree learned of the acquisition through press releases. Bernd Kammerer, then the chief operating officer of Everlight Americas, was in charge of the acquisition of Fairchild. He did not uncover Cree's accusation of infringement during the due diligence process leading up to the acquisition. He credibly claimed that, had he known of the accused infringement, he would have attempted to negotiate a lower purchase price, an indemnity agreement, or a contractual provision limiting Everlight's post-acquisition liability.
On April 18, 2007, in a meeting between representatives of Cree and Everlight, Cree provided Everlight with a Powerpoint presentation accusing Everlight of infringing the '738 patent. After this initial meeting, Everlight reached out to Epistar, its chip supplier, for assistance in defending against Cree's allegations. Epistar ordered independent testing of its accused LED chips and commissioned an IP law firm to provide an infringement opinion and to represent Everlight in discussions with Cree. Cree and Everlight continued their correspondence and, on January 16, 2008, Everlight provided Cree with the noninfringement analysis developed by Epistar in the form of a Powerpoint presentation. In that presentation, Everlight represented to Cree that, from 2002 to 2007, Everlight had only $4,194 in U.S. sales.
After the January 2008 meeting, Cree and Everlight reached a business solution, whereby Everlight agreed to buy more Cree chips. However, Cree never agreed to not file suit, and did not waive any of its infringement claims against Everlight. Nonetheless, from early 2008 to the filing of the present suit, Cree did not take any
In 2007, Everlight had total accused sales of $13.4 million which increased to $24 million in 2012. This expansion included developing an estimated 80 to 130 new LED packages every year that utilized GaN LED chips. During these years, Everlight invested approximately $10 million to $16 million per year in the research and development of new GaN LED packages. From 2007 to 2013, Everlight's sales to the United States accounted for less than 5% of its worldwide GaN LED package sales.
Since Everlight began purchasing GaN LED chips, it has purchased from several different suppliers including Epistar, Toyoda Gosei, Cree, and various Chinese companies. Cree manufactures noninfringing LED chips using a silicon carbide substrate. Everlight regularly alters its production line to adapt to chips from different suppliers using different substrates, a process which usually takes eight to ten weeks to complete. Silicon carbide chips, unlike the sapphire chips in the accused LED products, are used in high-performance applications, and are much more expensive.
"Laches is cognizable under 35 U.S.C. § 282 (1988) as an equitable defense to a claim for patent infringement."
[T]o invoke the laches defense, a defendant has the burden to prove two factors:
"The district court should consider these factors and all of the evidence and other circumstances to determine whether equity should intercede to bar pre-filing damages."
The availability of the laches defense was called into question recently, following the Supreme Court's decision in
The defendants rely on a "tacking" theory to support a presumption of laches. Because BU and Cree had knowledge of possible infringement by the defendants' predecessors more than six years before BU filed suit, Epistar and Everlight argue they are entitled to a presumption of laches. BU responds that the defendants have provided no evidence that they continued producing any of their predecessors' products after acquiring their businesses and argues that, if a presumption exists, BU has produced enough evidence to successfully rebut it.
"A presumption of laches arises where a patentee delays bringing suit for more than six years after the date the patentee knew or should have known of the alleged infringer's activity."
In order to pursue a "tacking" theory, the defendants must first show that the predecessors' products were the "the same or similar" to the accused products in this case or that the earlier products "embodied the same claimed features as the accused product[s]."
For "tacking" to apply, the defendants must also show that they are the successors-in-interest to the predecessor companies the plaintiff accused of infringement.
To support its "tacking" argument, Epistar relies on an internal draft report from 2002, written by Michael Pratt, the managing director of BU's office of technology development, which stated that United Epitaxy was among a group of different companies whose products infringed on the '738 patent. Epistar later merged with United Epitaxy. Similarly, Epistar highlights Cree's 2005 letter to Epitech accusing it of infringement and Epitech's later merger with Epistar. Epistar has put forth no evidence showing that it continued any of Epitech or United Epitaxy's products or that any of their products were the same or similar to the accused products in this suit. To the contrary, after Epistar acquired Epitech, Epistar "replaced all Epitech's products with Epistar's products." Bench Trial Tr., Docket No. 1681 at 143. Because Epistar failed to provide sufficient evidence that its predecessors' products were the same or similar to the accused products in this case, this Court need not address whether Epistar was the "successor-in-interest" to either Epitech or United Epitaxy. Epistar's "tacking" argument fails.
Epistar argued that, when Cree accused Everlight of infringement in 2007, Cree knew that Epistar was one of Everlight's chip suppliers and, therefore, Cree had knowledge of Epistar's infringement. However, because Everlight had multiple chip suppliers, Epistar has not proven that, in 2007, Cree knew of Epistar's infringing activities. Cree executives first met with Epistar in October 2010 to discuss licensing Cree's LED patent portfolio, which included the '738 patent. This Court finds that Cree was aware of Epistar's infringement during these licensing discussions in October 2010, less than six years from BU filing suit, and, thus, there is no presumption of laches with respect to Epistar.
Everlight supports its "tacking" argument with evidence that, in May 2004, Cree accused Fairchild of infringing the '738 patent. Because Everlight manufactured the products Fairchild sold back in 2004 and Cree accused those products of infringing, Everlight has put forth sufficient evidence that the accused Fairchild products were the same or similar to the accused Everlight products in this case. In 2006, Everlight purchased Fairchild's LED business assets so that it could sell directly to Fairchild's customers. Even though this was not a complete merger of corporate entities, there was still a formal transfer of Fairchild's LED business and customer base. Therefore, this Court finds that Everlight is the "successor-in-interest" to Fairchild's LED business. Because Everlight has satisfied the requirements for "tacking" and Cree knew of the Fairchild-Everlight LED business purchase in 2006, this Court finds that Cree's knowledge of Everlight's infringing activity "tacks" back to 2004, more than six years before BU filed this suit. Therefore, the presumption of laches applies with respect to Everlight.
The defendants argue that BU's stated reasons for its delay in filing suit do not provide sufficient evidence that the delay was reasonable or excusable, especially
"The length of time which may be deemed unreasonable has no fixed boundaries but rather depends on the circumstances."
Although decided based on copyright, the Supreme Court acknowledged in the context of laches that the owner need not sue all infringers because "[e]ven if an infringement is harmful, the harm may be too small to justify the cost of litigation."
"The equities may or may not require that the plaintiff communicate its reasons for delay to the defendant."
This Court finds that Cree was not aware of Epistar's infringement until October 2010 when the two companies met to discuss licensing Cree's LED patent portfolio. It is unclear exactly when these discussions ended, but negotiations between the patentee and accused infringer are a recognized excuse for delay.
Cree's knowledge of Everlight's infringement "tacks" back to May 2004, when it accused Fairchild of infringement. This period of delay was eight and a half years. From April 2007 until January 2008, Everlight and Cree were engaged in discussions about possible infringement and maintained regular communications to resolve the issue. As part of those negotiations, in January 2008, Everlight represented to Cree that, from 2002 to 2007, it had only $4,194 in U.S. sales.
In January 2008, Cree and Everlight reached a business solution, in which Everlight agreed to purchase more Cree chips. However, Julio Garceran, Cree's chief intellectual property counsel, credibly testified that there was never such an agreement and that Cree never waived any of its infringement claims against Everlight. While this Court finds that Everlight has failed to prove such a waiver or agreement, Everlight could reasonably have assumed Cree would not enforce its patent rights as a result of this détente. Cree did nothing to dispel this sanguinity.
So the question becomes whether the delays from May 2004 to April 2007, and from January 2008 to October 2012, were unreasonable. BU and Cree were engaged in litigation with Bridgelux and Honeywell over the '738 patent from September 2006 to March 2009. Everlight argues that this period of delay due to other litigation is inexcusable because BU never informed Everlight that it intended to file suit after the litigation concluded. While notice is not strictly required, Everlight could reasonably have relied on its business truce with Cree. Because there is no requirement that a patentee sue every infringer at once, however, the time period while BU and Cree were engaged in other litigation reasonably excuses that delay. The nine months BU spent conducting its pre-suit investigation in 2012 are also excusable. However, given BU's failure to provide any acceptable excuses for the periods from May 2004 to September 2006, and from March 2009 to October 2012, BU has failed to rebut the presumption of laches and Everlight has proven that these delays were unreasonable.
The defendants argue that they made substantial monetary investments in their GaN LED businesses based on their belief that their products did not infringe and, if BU had sued earlier they could have adjusted their methods of production, discontinued sales of infringing chips to the United States, secured contractual protections from customers, or simply bought noninfringing chips from other suppliers. The plaintiff responds that the defendants have failed to provide evidence that other companies could or would have sold them adequate numbers of noninfringing chips, or that it would have been financially feasible to design around the '738 patent. The plaintiff also contends that, because the sales of accused products for each defendant were a small percentage of their total sales, the defendants would not have undertaken other noninfringing efforts even if BU had sued earlier. Finally, BU argues that, at all times through trial, the defendants contended their products did not infringe and have not changed their behavior since the filing of this suit.
"Material prejudice to adverse parties resulting from the plaintiff's delay is essential to the laches defense."
"[E]conomic prejudice is not a simple concept but rather is likely to be a slippery issue to resolve."
"A nexus must be shown between the patentee's delay in filing suit and the expenditures; the alleged infringer must change his position because of and as a result of the delay."
The Court need not address material prejudice with respect to Epistar because Epistar has failed to prove that BU's delay in filing suit was unreasonable. Even if it were unreasonable, Epistar was unable to provide sufficient detail regarding the technical or economic feasibility of adjusting its production and sales practices to avoid infringement. Additionally, even though it knew of Cree's litigation against Bridgelux in 2008 and Cree's infringement accusations against Everlight in 2007, it adhered to its noninfringement position that its chip's buffer layer was single crystalline, making it unlikely that Epistar would have changed its infringing behavior had BU sued earlier.
To show economic prejudice, Everlight points to its expansion in the GaN LED market from 2007, when it had total accused sales of $13.4 million, to 2012, when its accused sales volume increased to $24 million, its development of 80 to 130 new LED packages for GaN LED chips per year, and its investment of $10 million to $16 million each year on the research and development of new GaN LED packages. When pressed, Bernd Kammerer could not provide the actual percentage of its costs directly attributable to designing packages for Epistar's infringing GaN LED chips or the economic impact of altering its production processes.
Kammerer testified that, had BU sued earlier, Everlight could have simply switched to noninfringing Cree chips, which have silicon carbide substrates. In response, BU persuasively points out that these Cree chips are much more expensive and designed for higher performance applications than the accused products with sapphire substrates. Silicon carbide is electrically conductive, while sapphire is not. Using a silicon carbide substrate would require a different LED package design, and would also require Everlight's customers to alter their product designs.
Additionally, Epistar provided Everlight with its noninfringement analysis and vehemently denied any wrongdoing. Epistar had also promised to indemnify Everlight for any litigation expenses incurred based on Everlight products using Epistar's chips. Everlight relied on Epistar's noninfringement analysis without conducting its own independent testing because Epistar would foot the bill if its position proved incorrect. Armed with Epistar's noninfringement analysis, Everlight protested its innocence through trial based on a disagreement about the crystallinity of its products' layers, the Court's claim construction, and the '738 patent's validity. From 2007 to 2013, Everlight's sales to the United States accounted for less than five percent of its worldwide GaN LED package sales.
This Court finds it unlikely that, had BU sued earlier, Everlight — with its close ties to Epistar, Epistar's noninfringement and invalidity analysis, and its indemnity agreement — would have ceased purchasing Epistar chips and altered its LED package design based on such a small percentage of its total worldwide sales. Because Everlight has failed to prove a nexus between BU's delay in filing suit and any economic prejudice, this Court finds for the plaintiff on the issue of laches with respect to Everlight.
Under 35 U.S.C. § 284, a court awards the successful claimant "damages adequate to compensate for the infringement... together with interest and costs as fixed by the court." "[P]rejudgment interest should ordinarily be awarded."
Unsurprisingly, the parties disagree on nearly every aspect of prejudgment interest: whether it should be awarded at all, when it should begin accruing, and at which rate it should accrue.
First, mustering the same laches arguments rejected above, the defendants contend that interest should be denied because BU allegedly delayed in bringing suit. BU argues that the laches and interest analyses are coextensive and that the Court should deny interest only if it finds that any delay caused the defendants material prejudice.
The Court finds that BU is entitled to prejudgment interest. The Supreme Court indicated that "it may be appropriate to limit prejudgment interest, or perhaps even deny it altogether, where the patent owner has been responsible for undue delay in prosecuting the lawsuit."
Second, the parties dispute when the interest clock should start ticking. BU argues that interest should begin accruing in January 2000, the date of the hypothetical negotiation; the defendants respond that interest can accrue no earlier than the date that each of the defendants received notice of the infringement.
"When interest begins or ends is not stated" in the text of § 284 itself.
BU emphasizes that, by agreement of the parties, the jury was instructed that the hypothetical negotiation was deemed to take place "at the time prior to when infringement began" and that the jury should "determine a one-time lump-sum payment that the infringer would have paid at the time of the hypothetical negotiation for a license covering all sales of the licensed product, both past and future." Trial Tr. — Day 10, Docket No. 1600 at 30, 35.
The defendants counter that prejudgment interest cannot be awarded for the time periods when damages are legally barred. The defendants identify two limits on patent damages that they say serve to similarly constrain an award of interest. First, § 286 states that "no recovery shall be had for any infringement committed more than six years prior to the filing of the complaint." 35 U.S.C. § 286. Second, "without adequate marking, `no damages shall be recovered by the patentee in any action for infringement, except on proof that the infringer was notified of the infringement and continued to infringe thereafter.'"
BU's argument benefits from some logical appeal, but suffers from a paucity of supporting caselaw. BU does not cite a single case in which interest began accruing from the date of a fictional negotiation hypothesized to have taken place more
BU is correct that interest often commences at the date of infringement, but its argument that interest should begin accruing in January 2000 misses the mark in two critical respects.
First, the parties did not stipulate to January 2000 as the date of infringement. The parties stipulated to a hypothetical negotiation taking place on that date, and while the hypothetical negotiation typically takes place "on the eve of infringement,"
More importantly, the date of infringement is not the only date that matters here:
The jury was instructed accordingly.
Damages were therefore unavailable, pursuant to § 286, before December 14, 2006 — six years before the suit was filed — and, pursuant to § 287(a), before each defendant had actual notice of infringement. Interest on the damages award cannot begin accruing before the underlying damages were available.
The Court agrees with the defendants that interest begins accruing for Epistar on December 14, 2006, for Everlight on April 18, 2007, and for Lite-On on December 14, 2012.
Third and finally, the parties disagree over the interest rate the Court should apply. BU proposes the Massachusetts statutory rate of 12%. In the alternative, BU requests a rate that mirrors the defendants' average cost of capital, BU's average returns on investment, or the prime rate. The defendants urge the Court to apply the Treasury Bill rate.
The Federal Circuit "has recognized that the district court has substantial discretion to determine the interest rate in patent infringement cases."
The Federal Circuit has endorsed the use of both the T-Bill rate and the prime rate.
The Court finds that the prime rate properly compensates BU for its foregone use of the unpaid royalty payments.
The Court awards interest in the amount of the relevant annual prime rates, compounded annually.
The parties agree that 28 U.S.C. § 1961 governs postjudgment interest in this case.
Postjudgment interest is awarded in accordance with § 1961.
The Court finds in favor of the plaintiff on the issue of laches. The plaintiff's Motion for Prejudgment and Postjudgment Interest (Docket No. 1604) is
Pursuant to the jury verdict, Defendant Epistar is
The plaintiff shall submit a proposed form of judgment conforming to this order by May 3, 2016.